Cancer Combination Therapy Using CDK and BCL-2 Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer treatments face high failure rates in clinical trials and individual patient responses vary, with many patients not responding to standard drugs, necessitating the development of synergistic drug combinations for enhanced anti-cancer activity.
Innovation Solution
Administering a therapeutically effective amount of a CDK inhibitor, such as voruciclib, in combination with a BCL-2 inhibitor or a proteasome inhibitor, to treat cancers like blood cancers and triple negative breast cancer, with the inhibitors potentially being administered concurrently or sequentially.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard cancer drugs are administered individually, then the treatment approach is simple and cost-effective, but many patients fail to respond and the anti-cancer activity is insufficient
Solution Approach 1:
The patent combines multiple cancer drugs with different mechanisms of action into a single treatment regimen. Specifically, it combines a first cancer drug (e.g., targeting cell cycle progression) with a second cancer drug (e.g., targeting apoptosis or angiogenesis) to achieve synergistic effects that improve patient response rates while managing treatment complexity through coordinated administration protocols
2Reliability
If drug combinations are used to enhance anti-cancer activity, then synergistic effects are achieved, but the treatment cost and complexity increase
Solution Approach 1:
The patent merges multiple drugs with complementary mechanisms into a unified treatment approach that achieves synergistic anti-cancer effects. The combination includes a first cancer drug and a second cancer drug that work together to enhance efficacy against resistant tumor cells while managing overall treatment complexity through structured administration guidelines
3Adaptability or versatility
If new cancer drugs are developed through traditional discovery processes, then novel therapies are created, but the development cost is high and the time required is lengthy
Solution Approach 1:
The patent applies preliminary action by pre-identifying and pre-characterizing multiple cancer drugs with different mechanisms of action before implementing combination therapies. This allows the treatment regimen to be designed and validated in advance, accelerating the overall development timeline while maintaining the adaptability to target various cancer types and resistance patterns
Data Source
AI summary
The disclosure herein provides combination therapies for the treatment of cancers such as Leukemia, lymphoma and triple negative breast cancer. The disclosure provides combination therapies of CDK inhibitors, e.g., a CDK inhibitor represented by Formula I:or a pharmaceutically acceptable salt thereof together with a BCL-2 inhibitor or proteasome inhibitor for the treatment of cancer.